4//SEC Filing
HESTERBERG LYNDAL K. 4
Accession 0001209191-18-035400
CIK 0001642380other
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 8:51 PM ET
Size
9.7 KB
Accession
0001209191-18-035400
Insider Transaction Report
Form 4
HESTERBERG LYNDAL K.
Sr VP, Research & Development
Transactions
- Award
Option to Purchase Common Stock
2018-05-23+150,000→ 150,000 totalExercise: $2.35Exp: 2028-05-22→ Common Stock (150,000 underlying)
Holdings
- 14,400
Option to Purchase Common Stock
Exercise: $4.70Exp: 2027-02-16→ Common Stock (14,400 underlying) - 25,000
Option to Purchase Common Stock
Exercise: $3.06Exp: 2026-02-15→ Common Stock (25,000 underlying) - 125,000
Option to Purchase Common Stock
Exercise: $4.05Exp: 2026-10-31→ Common Stock (125,000 underlying)
Footnotes (3)
- [F1]These options vest as to one-third of the shares on each of the completion of the clinical utility study for OncoCyte's DetermaVu product candidate, the filing of the Medicare dossier for the Medicare local coverage determination, and obtaining a Medicare local coverage determination for OncoCyte's DetermaVu product candidate.
- [F2]One quarter of the options vested on October 31, 2017, and the balance shall vest thereafter in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.
- [F3]One quarter of the options vested on February 15, 2017 and one quarter vested on February 15, 2018, and the balance shall vest upon the attainment of certain product development milestones, in each case depending upon continuous employment by the Company.
Documents
Issuer
OncoCyte Corp
CIK 0001642380
Entity typeother
Related Parties
1- filerCIK 0001689836
Filing Metadata
- Form type
- 4
- Filed
- Jun 3, 8:00 PM ET
- Accepted
- Jun 4, 8:51 PM ET
- Size
- 9.7 KB